CONTROLLING PRETERM LABOR: A NEW MOLECULAR APPROACH

早产和分娩是中国的一个主要健康问题 美国和世界各地。最近的统计数据表明， 尽管在过去的10年里，早产率没有变化 为解决这一问题所作的努力。早产率有 保持在所有交货量的8%至10%左右。 尽管大约30%的早产与 在母亲感染的情况下，早产的比例更大 特发性的。早产儿占我们新生儿的70% 死亡率，早产儿护理的估计费用为 每年大约10亿美元。 许多治疗剂已被应用于治疗 早产，而成功是有限的，并与潜力相关 对母婴健康的影响。没有一种疗法是有效的 允许怀孕到足月。成功是相对的，包括 只需延迟几天交货即可启动的好处 适当的类固醇治疗。 这种治疗的失败在很大程度上反映了我们的不完整 对人类劳动规律的理解。这份提案提出了 一种基于最新新技术的早产控制新方法 对人类特有的劳动方面的洞察。

Preterm labor and delivery represent a major health problem in the United States and around the world. Recent statistics indicate that the rate of preterm births has not changed over the past 10 years, in spite of efforts to address this problem. The rate of preterm birth has remained at approximately 8 percent to 10 percent of all deliveries. Although approximately 30 percent of preterm deliveries are associated with maternal infection, the larger fraction of preterm births are idiopathic. Preterm infants account for 70 percent of our neonatal mortality, and the estimated cost for the care of premature infants is approximately billion dollars annually. A number of therapeutic agents have been applied as treatments for preterm labor, and success has limited and associated with potential health consequences to mother and infant. No therapy is effective in allowing pregnancies to reach term. Success is relative, and includes the benefit of delay of delivery for only a few days to initiate appropriate steroid therapy. To a large degree this failure of therapeutics reflects our incomplete understanding of the regulation of human labor. This proposal presents a novel approach to address control of preterm labor based on recent new insights into the human-specific aspects of labor.